 |
|
|
| |
Effect of Second Generation Antipsychotics on Metabolic Variables in HIV-infected Adults on Long Term Antiretroviral Therapy
|
| |
| |
Reported by Jules Levin
IAC Wash Dc 2012 July 22-27
M. Ferrara1,2, A. Umlauf2, C. FitzSimons2, J.M. Meyer3, G. Guaraldi1, J. Allen McCutchan2, N.A. Duarte2, J.H. Atkinson2,4, I. Grant2, R.J. Ellis2 for the CHARTER Group.
1 Department of Psychiatry, University of Modena and Reggio Emilia, Modena, Italy, 2 HIV Neurobehavioral Research Program (HNRP), University of California, San Diego (UCSD), 220 Dickinson Street, Suite B, San Diego, CA 92103-8231, USA , 3 Department of Psychiatry, University of California, San Diego (UCSD), 9500 Gilman Drive, La Jolla CA 92093-0603, USA, 4 Psychiatry Service, VA San Diego Healthcare System, San Diego, CA, 92161
References
· Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, & Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis.
Am J Psychiatry 1999; 156: 1686-1696.
· Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA,
Ortiz-Barron L, & Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen
Psychiatry 2001; 58: 721-728.
· Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 Suppl 1: S141-148.
· Vergara-Rodriguez P, Vibhakar S, & Watts J. Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human
immunodeficiency virus and severe mental illness. Pharmacol Ther 2009; 124: 269-278
|
| |
|
|
|
|
|
